Silicon Laboratories stock
SLABNASDAQSilicon Laboratories Inc., TechnologyISIN US8269191024
45Score 45 out of 100, Weak
Price and trend
75 / 100
Price history
+74% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 3.6% above it.
Since June 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is at its 52-week high. Largest decline in 20 years: 61% (October 2007 to December 2008).
Chart figures for advanced users
- SMA 50$221.26
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$213.91
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$116.08
- The lowest closing price of the last twelve months.
- Resistance$222.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Silicon Laboratories Inc. belongs to the Semiconductors industry (United States) and, with a market value of $7.39B, is number 108 of 185 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $784.76M (up 34.3% year on year) and a loss of $64.91M.
- For fiscal 2026, analysts expect on average revenue of $925.92M (up 18%) and adjusted earnings per share of $2.91 (up 219.5%).
Show more
- MEQIRI Score 45 out of 100 (Weak): rank 693 of 857 in Technology, median 61.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Share buybacksShare count down 25% since 2020.Capital allocation 53
- More cash than debtCash $439.84M, financial debt $0.Stability 60
- Analysts expect strong earnings growthUp 29.9% a year through 2028 (estimates from 3 analysts).
Weaknesses
- Loss-makingLoss of $20.32M over the last 12 months.Fundamentals 40
- Turned to a lossEarnings per share from $2.61 in 2022 to −$1.98.Growth 32
- Volatile share priceVolatility 52% a year over the last 12 months.Stability 60
Its standout strengths are technical analysis and momentum, while profitability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price up very strongly over the past year
What lowers it
- price near its 52-week high
Valuation
Valuation signal
OvervaluedA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 3 Oct 2026, revenue rose 21.3% on the twelve months before. Revenue has changed sharply in recent years: $784.76M in 2025 after $584.39M in 2024.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 58%, operating −9%, net −8%. Last 12 months: net −2%.
Debt & balance sheet
latest quarterNo financial debt is reported on the balance sheet.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 10 Nov 2026EPS reported $1.05 (expected $0.85)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.910.0%
- Revenue
- $925.92M0.0%
- Earnings per share
- $4.510.0%
- Revenue
- $1.08B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $3.18M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Silicon Laboratories
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
857 rated companies in Technology
- This company
- 45
- Sector median
- 61
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Semiconductors
The next larger and next smaller companies by market value
- Tianshui Huatian Technology002185.SZ $7.9B47
- ROHM6963.T $7.69B40
- FormFactorFORM $7.51B65
- Anji Microelectronics Technology (Shanghai)688019.SS $7.42B76
- Sanan Optoelectronics600703.SS $7.13B31
- Henan Shijia Photons Technology688313.SS $6.97B61
- Zhejiang Jingsheng Mechanical & Electrical300316.SZ $6.88B44
- Shannon Semiconductor Technology300475.SZ $6.86B62
ETFs that hold Silicon Laboratories
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.44% | 0.30% | €185.82M |
| iShares Automation & Robotics UCITS ETF2B76 | 0.43% | 0.40% | €4.49B |
| Amundi MSCI Smart Cities UCITS ETF ACCAMEC | 0.32% | 0.45% | €59.77M |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.25% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.24% | 0.30% | €2.17B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.22% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.21% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.18% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 3 Jan 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 13 Feb 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.